Skip to content

Study · Not a test of the peptide alone · 2026

4 results

Co-agonism of GLP-1R and CTR/AMYR in the lateral dorsal tegmental nucleus produces additive effects on homeostatic and motivated feeding.

Sanchez-Navarro MJ, Zhang C, Schmidt HD, Hayes MR

Physiology & behavior15 Aug 2026

PMID42603595 (opens in a new tab)DOI10.1016/j.physbeh.2026.115478 (opens in a new tab)PepBankPUB-42603595
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cagrilintide.

  1. 01AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome

    In animals, co-administration of GLP-1R and CTR/AMYR agonists into the LDTg suppressed food intake more than either treatment alone.

    In plain wordsIn animals, giving both drugs into one brain area reduced eating more than giving either drug alone.

    Peptide
    Cagrilintide
    Outcome
    DecreaseFood intake
    Study

    n: not reported in source

    Comparator
    Either agonist alone
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    We also showed that co-administration of GLP-1R and CTR/AMYR agonists into the LDTg resulted in a greater suppression of food intake and reduction in body weight compared to either treatment alone.
    2 context sentences
    Summary · context
    CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide that shows greater efficacy for weight loss compared to GLP-1R and CTR/AMYR mono-agonists alone.
    Summary · context
    In this study, we investigate the laterodorsal tegmental nucleus (LDTg) as a central site of integration for GLP-1R and CTR/AMYR signaling, and explore the effect of co-agonism in this nucleus on feeding behavior.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  2. 02AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome

    In animals, co-administration of GLP-1R and CTR/AMYR agonists into the LDTg reduced body weight more than either treatment alone.

    In plain wordsIn animals, giving both drugs into one brain area lowered body weight more than giving either drug alone.

    Peptide
    Cagrilintide
    Outcome
    DecreaseBody weight
    Study

    n: not reported in source

    Comparator
    Either agonist alone
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    We also showed that co-administration of GLP-1R and CTR/AMYR agonists into the LDTg resulted in a greater suppression of food intake and reduction in body weight compared to either treatment alone.
    2 context sentences
    Summary · context
    CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide that shows greater efficacy for weight loss compared to GLP-1R and CTR/AMYR mono-agonists alone.
    Summary · context
    In this study, we investigate the laterodorsal tegmental nucleus (LDTg) as a central site of integration for GLP-1R and CTR/AMYR signaling, and explore the effect of co-agonism in this nucleus on feeding behavior.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  3. 03AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Efficacy outcome

    In an operant model, combined GLP-1R and CTR/AMYR agonist treatment in the LDTg significantly reduced motivation to self-administer a highly palatable food reward.

    In plain wordsIn animals, the combined treatment in one brain area reduced the drive to work for tasty food.

    Peptide
    Cagrilintide
    Outcome
    DecreaseMotivation to self-administer palatable food
    Study

    n: not reported in source

    Outcome group
    Appetite and food intake · Nervous system and cognition

    Source sentences

    Summary
    Finally, using an operant model, we found that this combinatorial treatment significantly reduced motivation to self-administer a highly palatable food reward.
    2 context sentences
    Summary · context
    CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide that shows greater efficacy for weight loss compared to GLP-1R and CTR/AMYR mono-agonists alone.
    Summary · context
    In this study, we investigate the laterodorsal tegmental nucleus (LDTg) as a central site of integration for GLP-1R and CTR/AMYR signaling, and explore the effect of co-agonism in this nucleus on feeding behavior.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

  4. 04AnimalNot a test of Cagrilintide aloneAnimal study (in vivo)Mechanism

    By FISH, glp-1r-expressing and ctr-expressing neurons form largely distinct populations within the LDTg.

    In plain wordsIn animal brain tissue, the cells that carry the GLP-1 receptor and the calcitonin receptor were mostly different cells.

    Peptide
    Cagrilintide
    Outcome
    Not applicableOverlap of glp-1r and ctr expressing neurons in the LDTg
    Study

    n: not reported in source

    Outcome group
    Receptor activity and mechanism · Nervous system and cognition

    Source sentences

    Summary
    We first performed fluorescence in situ hybridization (FISH) to show that glp-1r- and ctr-expressing neurons comprise largely distinct populations within the LDTg
    2 context sentences
    Summary · context
    CagriSema is a fixed-ratio combination of the long-acting GLP-1R agonist semaglutide and the calcitonin (CTR)/amylin receptor (AMYR) agonist cagrilintide that shows greater efficacy for weight loss compared to GLP-1R and CTR/AMYR mono-agonists alone.
    Summary · context
    In this study, we investigate the laterodorsal tegmental nucleus (LDTg) as a central site of integration for GLP-1R and CTR/AMYR signaling, and explore the effect of co-agonism in this nucleus on feeding behavior.

    In this study, Cagrilintide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cagrilintide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Versions 3 to 38Current

    28 Oct 2026, 02:04 UTC

    The same notice was added 36 times, first on 9 Oct 2026, 18:17 UTC. The status did not change between them.

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.